Workshop: Investment in CGT – Securing Funding for your Biotech Venture

19 Jan 2023
Commercializing Advanced Therapies

3:30pm Chair Introduction

Sven Kili, Chief Executive Officer, Antion Biosciences


3:35pm Presentation: Commercially Conscious Development: A Necessity in Today’s Biotech Market

  • Why it is critical in this market to consider commercialization in early stages of development
  • What are some of the key considerations that will make the most impact

Jennifer Chow, Chief Executive Officer, Chimeric Therapeutics


3:50pm Presentation: Risk Mitigation Strategies for Making your CGT Venture More Attractive to Investors

  • Indication choice – choosing the ‘market’
  • Clinical trial design – safety and efficacy data
  • Requirements for Final Therapeutic Product & Target Product Profiles
  • Application of Quality by Design (regressive and progressive planning with the final therapeutic product in mind)
  • Importance of Cross-Functional Teams and selection of a de-risked plan
  • Company-investor matching. Importance of seeing investor as ‘one of the team’ and not a ‘means to an end’
  • Joining Standardization Groups like ISCBI, GAiT and ISCT assist in derisking

Stephen Sullivan, Founder, Lindville Bio


3:35pm Presentation: Advice for Startups in the New Normal – Best Practices to Secure the Right Funding & Thrive

• Know Your Investor
• Alternative funding sources
• Strategic relationships
• Futureproof & ways of extending runway

Daniella Kranjac, Founding Partner, Dynamk Capital


4:05pm Presentation: Working with Pharma to Advance Cell Therapies from Corporate Venture Investment to Partnering

  • What is pharma looking for in cell therapy deals
  • What are the key issues, challenges?
  • What are the key investment themes for pharma partners

Konstantina Katcheves, Senior Vice President Business Development, Bristol Myers Squibb


4:20pm Closing Panel with Q&A

With all session participants, joined by:

Miguel Forte, President-Elect, International Society for Cell & Gene Therapy

Jacob Becraft, CEO, Strand Therapeutics


Daniella Kranjac
Founding Partner
Dynamk Capital
Jacob Becraft
Co-Founder & CEO
Strand Therapeutics
Jennifer Chow
Chief Executive Officer & Managing Director
Chimeric Therapeutics
Konstantina Katcheves
Senior Vice President Business Development
Bristol Myers Squibb
Sven Kili
Chief Executive Officer
Antion Biosciences
Miguel Forte
President Elect
International Society for Cell & Gene Therapy